Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 21;2(3):105-9.
doi: 10.1016/j.jbo.2013.05.002. eCollection 2013 Sep.

Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey

Brian Hutton  1 , Patricia Morretto  2 , Urban Emmenegger  3 , Sasha Mazzarello  2 , Iryna Kuchuk  2 , Christina L Addison  4 , Freya Crawley  2 , Christine Canil  2 , Shawn Malone  5 , Scott Berry  3 , Dean Fergusson  1 , Mark Clemons  6
Affiliations

Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey

Brian Hutton et al. J Bone Oncol. .

Abstract

Background: In order to design studies assessing the optimal use of bone-targeted agents (BTAs) patient input is clearly desirable.

Methods: Patients who were receiving a BTA for metastatic prostate or breast cancer were surveyed at two Canadian cancer centres. Statistical analysis of respondent data was performed to establish relevant proportions of patient responses.

Results: Responses were received from 141 patients, 76 (53.9%) with prostate cancer and 65 (46.1%) with breast cancer. Duration of BTA use was <3 months (15.9%) to >24 months (35.2%). Patients were uncertain how long they would remain on a BTA. While most felt their BTA was given to reduce the chance of bone fractures (77%), 52% thought it would slow tumour growth. Prostate patients were more likely to receive denosumab and breast cancer patients, pamidronate. There was more variability in the dosing interval for breast cancer patients. Given a choice, most patients (49-57%) would prefer injection therapy to oral therapy (21-23%). Most patients (58-64%) were interested in enrolling in clinical trials of de-escalated therapy.

Conclusion: While there were clear differences in the types of BTAs patients received, our survey showed similarity for both prostate and breast cancer patients with respect to their perceptions of the goals of therapy. Patients were interested in participating in trials of de-escalated therapy. However, given that patients receive a range of agents for varying periods of time and in different locations (e.g. hospital vs. home), the design of future trials will need to be pragmatic to reflect this.

Keywords: Bone metastases; Breast cancer; Patients; Prostate cancer; Survey.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Summary of bone-targeted agents patients were currently receiving.
Fig. 2
Fig. 2
Summary of where respondents currently receive their bone-targeted therapy.
Fig. 3
Fig. 3
Frequency of bone-targeted agent administration.
Fig. 4
Fig. 4
Summary of why patients believe they receive bone-targeted treatment.
See this image and copyright information in PMC

References

    1. Kuchuk I, Clemons M, Addison C. Time to put an end to the one size fits all approach tobisphosphonate use in patients with metastatic breast cancer? Current Oncology. 2012;19(5):e303–e304. - PMC - PubMed
    1. Amadori D, Aglietta M, Alessi B. ZOOM: A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone metastatic breast cancer (BC) after 1 yr of standard ZOL treatment. Journal of Clinical Oncology. 2012;30(9005)
    1. Amir E, Freedman O, Carlsson L. Randomized feasibility study of de-escalated (Every 12 wk) versus standard (Every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. American Journal of Clinical Oncology. 2012 published online first. - PubMed
    1. Coleman R. Bone cancer in 2011: prevention and treatment of bone metastases. Nature Reviews Clinical Oncology. 2011;9(2):76–78. - PubMed
    1. Coleman RE, Wright, J, Houston, S, et al..Randomized trial of marker-directed versusstandard schedule zoledronic acid for bone metastases from breast cancer, ASCO Annual Meeting 2012 Chicago, IL, Journal of Clinical Oncology, pp 511. 2012.

LinkOut - more resources